Examining the mechanisms and clinical potential of a promising non-opioid pain therapy candidate

SRP-001’s absent hepatotoxicity is due to lack of NAPQI formation and maintenance of hepatic tight junction integrity. Credit: Scientific Reports (2024). DOI: 10.1038/s41598-024-61791-z A recent publication in Scientific Reports unveils a promising non-opioid pain treatment developed by a team led by Dr. Hernan Bazan, the John Ochsner Endowed Professor of Cardiovascular Innovation at Ochsner Health. The study, titled “Transcriptomic Signature, Bioactivity, and Safety of an Analgesic Generating AM404 in the Midbrain PAG Region,” introduces SRP-001, a novel medication in development by South Rampart Pharma, Inc., co-founded by Dr. Bazan. The Read More